A systematic review on the association between ovarian and prostate cancer with BRCA1 and BRCA2 gene
Сибирский онкологический журнал, 2023 Background. BRCA1 and BRCA2 were discussed as the basis of inherited adenocarcinoma and breast and ovarian malignancy. Ovarian cancer is uncommon in women below 40 years of age, and prostate cancer mainly occurs in older men cause 90 % in those above ...
Sarpparajan Chitra Veena +2 more
doaj +1 more source
BRCA1/2 associated cancer susceptibility: a clinical overview
Forum of Clinical Oncology, 2016 The most frequently identified genetic cause of breast cancer is the germline mutation of BRCA1 and 2 genes. The carriers of these mutations are at high risk for breast and ovarian cancers and increased risk for pancreatic and prostate cancers.
Lypas Georgios
doaj +1 more source
BRCA2 and homologous recombination [PDF]
Breast Cancer Research, 2001 Two recent papers provide new evidence relevant to the role of the breast cancer susceptibility gene BRCA2 in DNA repair. Moynahan et al provide genetic data indicating a requirement for BRCA2 in homology-dependent (recombinational) repair of DNA double-strand breaks.
B J, Orelli, D K, Bishop
openaire +2 more sources
Founder mutations in Nepalese population [PDF]
Journal of Pathology and Translational Medicine, 2022 Background Founder mutation is a heritable genetic alteration observed with high frequency in a geographically and culturally isolated population where one or more ancestors becomes the forebearer of the altered gene.
Anurag Mehta +5 more
doaj +1 more source
RPA, RFWD3 and BRCA2 at stalled forks: a balancing act
Molecular & Cellular Oncology, 2020 We recently identified E3 ligase RFWD3 as a modulator of stalled fork stability in BRCA2-deficient cells. We also show that BRCA1 might function upstream of BRCA2 during fork repair and that blocking fork degradation by depleting MRE11 does not guarantee
Haohui Duan, Shailja Pathania
doaj +1 more source
A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
Case Reports in Oncology, 2021 We report a rare case of hereditary breast and ovarian cancer syndrome (HBOC) with pathogenic variants in both BRCA1 and BRCA2. The patient was a 78-year-old woman who visited the hospital after noticing a lump in her left breast 6 months before, which ...
Miyuki Kitahara +3 more
doaj +1 more source
Risk of Breast and Ovarian Cancer After Prophylactic Mastectomy and Salpingo-Oophorectomy in BRCA1/2 Germline Variant Carriers: A Retrospective Cohort Study From a Single German Center. [PDF]
Cancer MedABSTRACT Background As the data on BRCA1/2‐associated breast and ovarian cancer prevalence after prophylactic surgery has not been exhaustively investigated yet, we aimed to evaluate the cancer prevalence in a single center cohort of BRCA1 and BRCA2 carriers after conducting prophylactic mastectomy, as well as prophylactic bilateral salpingo ...
Mendes S +4 more
europepmc +2 more sources
Detection of BRCA2 Genes Polymorphism among Prostate Cancer Patients in Sudan 2020: A Case-Control Study [PDF]
Journal of Liaquat National HospitalBackground: Prostate cancer (PCa) has been associated with BRCA2 mutations; however, reported risk estimates differ greatly, mainly because of variations in retrospective study designs.
Randa Elginad +7 more
doaj +1 more source
BRCA1/2 Expression Patterns in Different Grades of Oral Squamous Cell Carcinoma [PDF]
Middle East Journal of Cancer, 2020 Background: Oral squamous cell carcinoma (OSCC) is the sixth most common cancer worldwide and has a poor prognosis. The breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes are the key tumor suppressor genes responding in the cases of DNA damage ...
Soussan Irani, Mitra Rafizadeh
doaj +1 more source
Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing [PDF]
Journal of Immunotherapy and Precision OncologyIntroduction Genomic profiling is performed in patients with advanced or metastatic cancer, in order to direct cancer treatment, often sequencing tumor-only, without a matched germline comparator.
Carol J. Nowlen +18 more
doaj +1 more source